Livou Group (000513.SZ): Injectable ariprazole microspheres obtained registration approval

Zhitong Finance App News, Lizhu Group (000513.SZ) issued an announcement. Recently, the company's wholly-owned subsidiary, Zhuhai Lizhu Microsphere Technology Co., Ltd. (hereinafter referred to as “Lizhu Microsphere”), received the “Drug Registration Certificate” (certificate number: 2025S01188) approved and issued by the State Drug Administration, and injectable aripiprazole microspheres were approved for listing.

The marketing application for injectable ariprazole microspheres was submitted in September 2023. The acceptance number is: CXHS2300080. Injectable ariprazole microspheres are long-acting sustained-release formulations independently developed by LEJU Microspheres. The indications are adult schizophrenia. The administration of injectable ariprazole microspheres once a month can improve medication compliance, help reduce recurrence and hospitalization rates, and reduce the financial and social burden on patients.